[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 823
Citations 0
Comment & Response
April 9, 2014

Dual Antiplatelet Therapy After Stent Implantation

Author Affiliations
  • 1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 2Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 3Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
JAMA. 2014;311(14):1446. doi:10.1001/jama.2014.2092

To the Editor The Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) trial1 contributes to the body of evidence supporting an improved safety profile of second-generation drug-eluting stents compared with first-generation models.2 However, although it is tempting to simplify the question of the duration of dual antiplatelet therapy to one of stent model or generation, data must be carefully viewed in the context of multiple patient and clinical trial characteristics other than the type of stent involved.

First Page Preview View Large
First page PDF preview
First page PDF preview
×